{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:19:16Z","timestamp":1772119156637,"version":"3.50.1"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,9,21]],"date-time":"2024-09-21T00:00:00Z","timestamp":1726876800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,21]],"date-time":"2024-09-21T00:00:00Z","timestamp":1726876800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82260584"],"award-info":[{"award-number":["82260584"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81773015"],"award-info":[{"award-number":["81773015"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2019YFE0108100"],"award-info":[{"award-number":["2019YFE0108100"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s00277-024-06009-y","type":"journal-article","created":{"date-parts":[[2024,9,21]],"date-time":"2024-09-21T07:01:29Z","timestamp":1726902089000},"page":"5495-5510","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Distinct pathway activities are associated with prognosis and response to bortezomib-containing treatment in MCL1-M based molecular subtypes of multiple myeloma"],"prefix":"10.1007","volume":"103","author":[{"given":"Yuan","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sitao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hang","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingling","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pengli","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiuyi","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanfei","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayaz Ali","family":"Samo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuzhang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaolong","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,9,21]]},"reference":[{"key":"6009_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers13061285","volume":"13","author":"A Schavgoulidze","year":"2021","unstructured":"Schavgoulidze A, Cazaubiel T, Perrot A et al (2021) Multiple myeloma: heterogeneous in every way. Cancers (Basel) 13:1\u201311. https:\/\/doi.org\/10.3390\/cancers13061285","journal-title":"Cancers (Basel)"},{"key":"6009_CR2","doi-asserted-by":"publisher","unstructured":"Vo JN, Wu YM, Mishler J et al (2022) The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myeloma. Nat Commun 13. https:\/\/doi.org\/10.1038\/s41467-022-31430-0","DOI":"10.1038\/s41467-022-31430-0"},{"key":"6009_CR3","doi-asserted-by":"publisher","unstructured":"Pawlyn C, Davies FE (2019) Toward personalized treatment in multiple myeloma based on molecular characteristics. Blood 133. https:\/\/doi.org\/10.1182\/blood-2018-09-825331","DOI":"10.1182\/blood-2018-09-825331"},{"key":"6009_CR4","doi-asserted-by":"publisher","first-page":"e1169","DOI":"10.1200\/jop.19.00639","volume":"16","author":"Y Yu","year":"2020","unstructured":"Yu Y, Brown Wade N, Hwang AE et al (2020) Variability in Cytogenetic Testing for multiple myeloma: a Comprehensive Analysis from across the United States. JCO Oncol Pract 16:e1169\u2013e1180. https:\/\/doi.org\/10.1200\/jop.19.00639","journal-title":"JCO Oncol Pract"},{"key":"6009_CR5","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1182\/blood-2005-11-013458","volume":"108","author":"F Zhan","year":"2006","unstructured":"Zhan F, Huang Y, Colla S et al (2006) The molecular classification of multiple myeloma. Blood 108:2020\u20132028. https:\/\/doi.org\/10.1182\/blood-2005-11-013458","journal-title":"Blood"},{"key":"6009_CR6","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1182\/blood-2006-07-038430","volume":"109","author":"JD Shaughnessy","year":"2007","unstructured":"Shaughnessy JD, Zhan F, Burington BE et al (2007) Avalidated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 109:2276\u20132284. https:\/\/doi.org\/10.1182\/blood-2006-07-038430","journal-title":"Blood"},{"key":"6009_CR7","doi-asserted-by":"publisher","first-page":"4798","DOI":"10.1200\/JCO.2007.13.8545","volume":"26","author":"O Decaux","year":"2008","unstructured":"Decaux O, Lod\u00e9 L, Magrangeas F et al (2008) Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone Du My\u00e9lom. J Clin Oncol 26:4798\u20134805. https:\/\/doi.org\/10.1200\/JCO.2007.13.8545","journal-title":"J Clin Oncol"},{"key":"6009_CR8","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1182\/blood-2015-05-644039","volume":"126","author":"R Kuiper","year":"2015","unstructured":"Kuiper R, Van Duin M, Van Vliet MH et al (2015) Prediction of high- and low-risk multiple myeloma based on gene expression and the International Staging System. Blood 126:1996\u20132004. https:\/\/doi.org\/10.1182\/blood-2015-05-644039","journal-title":"Blood"},{"key":"6009_CR9","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1002\/gcc.2","volume":"57","author":"AA Samo","year":"2018","unstructured":"Samo AA, Li J, Zhou M et al (2018) MCL1 gene co-expression module stratifies multiple myeloma and predicts response to proteasome inhibitor-based therapy. Genes Chromosomes Cancer 57:420\u2013429. https:\/\/doi.org\/10.1002\/gcc.2","journal-title":"Genes Chromosomes Cancer"},{"key":"6009_CR10","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/ni.2527","volume":"14","author":"V Peperzak","year":"2013","unstructured":"Peperzak V, Vikstr\u00f6m I, Walker J et al (2013) Mcl-1 is essential for the survival of plasma cells. Nat Immunol 14:290\u2013297. https:\/\/doi.org\/10.1038\/ni.2527","journal-title":"Nat Immunol"},{"key":"6009_CR11","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1182\/blood.V99.6.1885","volume":"99","author":"B Zhang","year":"2002","unstructured":"Zhang B, Gojo I, Fenton RG (2002) Myeloid cell factor-1 is a critical survival factor for multiple myeloma. Blood 99:1885\u20131893. https:\/\/doi.org\/10.1182\/blood.V99.6.1885","journal-title":"Blood"},{"key":"6009_CR12","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1006\/cbir.2000.0497","volume":"24","author":"K Gad\u00f3","year":"2000","unstructured":"Gad\u00f3 K, Domj\u00e1n G, Hegyesi H, Falus A (2000) Role of interleukin-6 in the pathogenesis of multiple myeloma. Cell Biol Int 24:195\u2013209. https:\/\/doi.org\/10.1006\/cbir.2000.0497","journal-title":"Cell Biol Int"},{"key":"6009_CR13","doi-asserted-by":"publisher","unstructured":"Walker BA, Leone PE, Chiecchio L et al (2010) A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. Blood 116. https:\/\/doi.org\/10.1182\/blood-2010-04-279596","DOI":"10.1182\/blood-2010-04-279596"},{"key":"6009_CR14","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1182\/blood-2012-03-415588","volume":"120","author":"A Seckinger","year":"2012","unstructured":"Seckinger A, Mei\u00dfner T, Moreaux J et al (2012) Clinical and prognostic role of annexin A2 in multiple myeloma. Blood 120:1087\u20131094. https:\/\/doi.org\/10.1182\/blood-2012-03-415588","journal-title":"Blood"},{"key":"6009_CR15","doi-asserted-by":"publisher","unstructured":"Ohguchi H, Hideshima T, Bhasin MK et al (2016) The KDM3A-KLF2-IRF4 axis maintains myeloma cell survival. Nat Commun 7. https:\/\/doi.org\/10.1038\/ncomms10258","DOI":"10.1038\/ncomms10258"},{"key":"6009_CR16","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1182\/blood-2009-12-261032","volume":"116","author":"A Broyl","year":"2010","unstructured":"Broyl A, Hose D, Lokhorst H et al (2010) Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients. Blood 116:2543\u20132553. https:\/\/doi.org\/10.1182\/blood-2009-12-261032","journal-title":"Blood"},{"key":"6009_CR17","doi-asserted-by":"publisher","unstructured":"Danziger SA, McConnell M, Gockley J et al (2020) Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: a cohort study of patients in the total therapy clinical trials. PLoS Med 17. https:\/\/doi.org\/10.1371\/journal.pmed.1003323","DOI":"10.1371\/journal.pmed.1003323"},{"key":"6009_CR18","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/nature09837","volume":"471","author":"MA Chapman","year":"2011","unstructured":"Chapman MA, Lawrence MS, Keats JJ et al (2011) Initial genome sequencing and analysis of multiple myeloma. Nature 471:467\u2013472. https:\/\/doi.org\/10.1038\/nature09837","journal-title":"Nature"},{"key":"6009_CR19","doi-asserted-by":"publisher","first-page":"3177","DOI":"10.1182\/blood-2006-09-044974","volume":"109","author":"G Mulligan","year":"2007","unstructured":"Mulligan G, Mitsiades C, Bryant B et al (2007) Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood 109:3177\u20133188. https:\/\/doi.org\/10.1182\/blood-2006-09-044974","journal-title":"Blood"},{"key":"6009_CR20","doi-asserted-by":"publisher","unstructured":"B\u00f8gsted M, Bilgrau AE, Wardell CP et al (2013) Proof of the concept to use a malignant B cell line drug screen strategy for identification and weight of melphalan resistance genes in multiple myeloma. PLoS ONE 8. https:\/\/doi.org\/10.1371\/journal.pone.0083252","DOI":"10.1371\/journal.pone.0083252"},{"key":"6009_CR21","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1182\/blood-2006-07-037077","volume":"109","author":"F Zhan","year":"2007","unstructured":"Zhan F, Barlogie B, Arzoumanian V et al (2007) Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. Blood 109:1692\u20131700. https:\/\/doi.org\/10.1182\/blood-2006-07-037077","journal-title":"Blood"},{"key":"6009_CR22","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.clml.2019.01.003","volume":"19","author":"SR Goldsmith","year":"2019","unstructured":"Goldsmith SR, Fiala MA, Dukeman J et al (2019) Next generation sequencing-based validation of the revised International Staging System for multiple myeloma: an analysis of the MMRF CoMMpass Study. Clin Lymphoma Myeloma Leuk 19:285\u2013289. https:\/\/doi.org\/10.1016\/j.clml.2019.01.003","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"6009_CR23","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1182\/blood.2020009754","volume":"138","author":"D Alameda","year":"2021","unstructured":"Alameda D, Goicoechea I, Vicari M et al (2021) Tumor cells in light-chain amyloidosis and myeloma show distinct transcriptional rewiring of normal plasma cell development. Blood 138:1583\u20131589. https:\/\/doi.org\/10.1182\/blood.2020009754","journal-title":"Blood"},{"key":"6009_CR24","doi-asserted-by":"publisher","first-page":"6388","DOI":"10.1073\/pnas.1219651110","volume":"110","author":"Y Drier","year":"2013","unstructured":"Drier Y, Sheffer M, Domany E (2013) Pathway-based personalized analysis of cancer. Proc Natl Acad Sci U S A 110:6388\u20136393. https:\/\/doi.org\/10.1073\/pnas.1219651110","journal-title":"Proc Natl Acad Sci U S A"},{"key":"6009_CR25","doi-asserted-by":"publisher","unstructured":"H\u00e4nzelmann S, Castelo R, Guinney J (2013) GSVA: Gene set variation analysis for microarray and RNA-Seq data. https:\/\/doi.org\/10.1186\/1471-2105-14-7. BMC Bioinformatics 14:","DOI":"10.1186\/1471-2105-14-7"},{"key":"6009_CR26","doi-asserted-by":"crossref","unstructured":"Korotkevich G, Sukhov V, Budin N et al (2016) Fast gene set enrichment analysis","DOI":"10.1101\/060012"},{"key":"6009_CR27","doi-asserted-by":"publisher","first-page":"5002","DOI":"10.1182\/blood-2011-07-368142","volume":"120","author":"S Blotta","year":"2012","unstructured":"Blotta S, Jakubikova J, Calimeri T et al (2012) Canonical and noncanonical hedgehog pathway in the pathogenesis of multiple myeloma. Blood 120:5002\u20135013. https:\/\/doi.org\/10.1182\/blood-2011-07-368142","journal-title":"Blood"},{"key":"6009_CR28","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.bone.2010.05.036","volume":"48","author":"T Matsumoto","year":"2011","unstructured":"Matsumoto T, Abe M (2011) TGF-\u03b2-related mechanisms of bone destruction in multiple myeloma. Bone 48:129\u2013134. https:\/\/doi.org\/10.1016\/j.bone.2010.05.036","journal-title":"Bone"},{"key":"6009_CR29","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1038\/leu.2012.127","volume":"26","author":"R Kuiper","year":"2012","unstructured":"Kuiper R, Broyl A, De Knegt Y et al (2012) A gene expression signature for high-risk multiple myeloma. Leukemia 26:2406\u20132413. https:\/\/doi.org\/10.1038\/leu.2012.127","journal-title":"Leukemia"},{"key":"6009_CR30","doi-asserted-by":"publisher","first-page":"a001115","DOI":"10.1101\/mcs.a001115","volume":"3","author":"VR Holla","year":"2017","unstructured":"Holla VR, Elamin YY, Bailey AM et al (2017) ALK: a tyrosine kinase target for cancer therapy. Cold Spring Harb Mol Case Stud 3:a001115. https:\/\/doi.org\/10.1101\/mcs.a001115","journal-title":"Cold Spring Harb Mol Case Stud"},{"key":"6009_CR31","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1080\/10428194.2018.1493727","volume":"60","author":"K Cai","year":"2019","unstructured":"Cai K, Na W, Guo M et al (2019) Targeting the cross-talk between the hedgehog and NF-\u03baB signaling pathways in multiple myeloma. Leuk Lymphoma 60:772\u2013781. https:\/\/doi.org\/10.1080\/10428194.2018.1493727","journal-title":"Leuk Lymphoma"},{"key":"6009_CR32","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13045-018-0615-3","volume":"11","author":"I Spaan","year":"2018","unstructured":"Spaan I, Raymakers RA, van de Stolpe A, Peperzak V (2018) Wnt signaling in multiple myeloma: a central player in disease with therapeutic potential. J Hematol Oncol 11:67. https:\/\/doi.org\/10.1186\/s13045-018-0615-3","journal-title":"J Hematol Oncol"},{"key":"6009_CR33","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.7150\/jca.18808","volume":"8","author":"L Lin","year":"2017","unstructured":"Lin L, Zhang X, Cao L et al (2017) Reelin promotes adhesion of multiple myeloma cells to bone marrow stromal cells via integrin \u03b21 signaling. J Cancer 8:2212\u20132222. https:\/\/doi.org\/10.7150\/jca.18808","journal-title":"J Cancer"},{"key":"6009_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers13020216","volume":"13","author":"T Hideshima","year":"2021","unstructured":"Hideshima T, Anderson KC (2021) Signaling pathway mediating myeloma cell growth and survival. Cancers (Basel) 13:1\u201317. https:\/\/doi.org\/10.3390\/cancers13020216","journal-title":"Cancers (Basel)"},{"key":"6009_CR35","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1084\/jem.20051395","volume":"202","author":"C Asselin-Paturel","year":"2005","unstructured":"Asselin-Paturel C, Trinchieri G (2005) Production of type I interferons: plasmacytoid dendritic cells and beyond. J Exp Med 202:461\u2013465. https:\/\/doi.org\/10.1084\/jem.20051395","journal-title":"J Exp Med"},{"key":"6009_CR36","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/nri3581","volume":"14","author":"LB Ivashkiv","year":"2014","unstructured":"Ivashkiv LB, Donlin LT (2014) Regulation of type i interferon responses. Nat Rev Immunol 14:36\u201349. https:\/\/doi.org\/10.1038\/nri3581","journal-title":"Nat Rev Immunol"},{"key":"6009_CR37","doi-asserted-by":"publisher","unstructured":"Lundell AC, Nordstr\u00f6m I, Andersson K et al (2017) IFN type i and II induce BAFF secretion from human decidual stromal cells. Sci Rep 7. https:\/\/doi.org\/10.1038\/srep39904","DOI":"10.1038\/srep39904"},{"key":"6009_CR38","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.ccr.2009.08.019","volume":"16","author":"D Chauhan","year":"2009","unstructured":"Chauhan D, Singh AV, Brahmandam M et al (2009) Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target. Cancer Cell 16:309\u2013323. https:\/\/doi.org\/10.1016\/j.ccr.2009.08.019","journal-title":"Cancer Cell"},{"key":"6009_CR39","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1136\/annrheumdis-2015-207392","volume":"75","author":"Z Brkic","year":"2016","unstructured":"Brkic Z, van Bon L, Cossu M et al (2016) The interferon type I signature is present in systemic sclerosis before overt fibrosis and might contribute to its pathogenesis through high BAFF gene expression and high collagen synthesis. Ann Rheum Dis 75:1567\u20131573. https:\/\/doi.org\/10.1136\/annrheumdis-2015-207392","journal-title":"Ann Rheum Dis"},{"key":"6009_CR40","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.20517\/cdr.2021.93","volume":"4","author":"M Moscvin","year":"2021","unstructured":"Moscvin M, Ho M, Bianchi G (2021) Overcoming drug resistance by targeting protein homeostasis in multiple myeloma. Cancer Drug Resist 4:1028\u20131046. https:\/\/doi.org\/10.20517\/cdr.2021.93","journal-title":"Cancer Drug Resist"},{"key":"6009_CR41","doi-asserted-by":"publisher","first-page":"4907","DOI":"10.1182\/blood-2005-08-3531","volume":"107","author":"EA Obeng","year":"2006","unstructured":"Obeng EA, Carlson LM, Gutman DM et al (2006) Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 107:4907\u20134916. https:\/\/doi.org\/10.1182\/blood-2005-08-3531","journal-title":"Blood"},{"key":"6009_CR42","doi-asserted-by":"publisher","first-page":"9946","DOI":"10.1073\/pnas.1334037100","volume":"100","author":"AH Lee","year":"2003","unstructured":"Lee AH, Iwakoshi NN, Anderson KC, Glimcher LH (2003) Proteasome inhibitors disrupt the unfolded protein response in myeloma cells. Proc Natl Acad Sci U S A 100:9946\u20139951. https:\/\/doi.org\/10.1073\/pnas.1334037100","journal-title":"Proc Natl Acad Sci U S A"},{"key":"6009_CR43","doi-asserted-by":"publisher","unstructured":"Borjan B, Kern J, Steiner N et al (2020) Spliced XBP1 levels determine sensitivity of multiple myeloma cells to proteasome inhibitor Bortezomib Independent of the unfolded protein response mediator GRP78. Front Oncol 9. https:\/\/doi.org\/10.3389\/fonc.2019.01530","DOI":"10.3389\/fonc.2019.01530"},{"key":"6009_CR44","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.1200\/JCO.2011.39.6820","volume":"30","author":"P Sonneveld","year":"2012","unstructured":"Sonneveld P, Schmidt-Wolf IGH, Van Der Holt B et al (2012) Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65\/ GMMG-HD4 trial. J Clin Oncol 30:2946\u20132955. https:\/\/doi.org\/10.1200\/JCO.2011.39.6820","journal-title":"J Clin Oncol"},{"key":"6009_CR45","first-page":"2950","volume":"12","author":"S Bal","year":"2022","unstructured":"Bal S, Kumar SK, Fonseca R et al (2022) Multiple myeloma with t(11;14): unique biology and evolving landscape. Am J Cancer Res 12:2950\u20132965","journal-title":"Am J Cancer Res"},{"key":"6009_CR46","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1182\/blood-2017-06-788786","volume":"130","author":"S Kumar","year":"2017","unstructured":"Kumar S, Kaufman JL, Gasparetto C et al (2017) Efficacy of venetoclax as targeted therapy for relapsed\/refractory t(11;14) multiple myeloma. Blood 130:2401\u20132409. https:\/\/doi.org\/10.1182\/blood-2017-06-788786","journal-title":"Blood"},{"key":"6009_CR47","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1111\/j.0105-2896.2006.00373.x","volume":"210","author":"AL Shaffer","year":"2006","unstructured":"Shaffer AL, Wright G, Yang L et al (2006) A library of gene expression signatures to illuminate normal and pathological lymphoid biology. Immunol Rev 210:67\u201385. https:\/\/doi.org\/10.1111\/j.0105-2896.2006.00373.x","journal-title":"Immunol Rev"},{"key":"6009_CR48","doi-asserted-by":"publisher","first-page":"2778","DOI":"10.1182\/blood-2018-09-876433","volume":"132","author":"A Cleynen","year":"2018","unstructured":"Cleynen A, Samur M, Perrot A et al (2018) Variable BCL2\/BCL2L1 ratio in multiple myeloma with t(11;14). Blood 132:2778\u20132780. https:\/\/doi.org\/10.1182\/blood-2018-09-876433","journal-title":"Blood"},{"key":"6009_CR49","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1158\/1535-7163.MCT-15-0730","volume":"15","author":"EA Punnoose","year":"2016","unstructured":"Punnoose EA, Leverson JD, Peale F et al (2016) Expression profile of BCL-2, BCL-XL, and MCL-1 predicts pharmacological response to the BCL-2 selective antagonist venetoclax in multiple myeloma models. Mol Cancer Ther 15:1132\u20131144. https:\/\/doi.org\/10.1158\/1535-7163.MCT-15-0730","journal-title":"Mol Cancer Ther"},{"key":"6009_CR50","doi-asserted-by":"publisher","unstructured":"Harmer D, Falank C, Reagan MR (2019) Interleukin-6 interweaves the bone marrow microenvironment, bone loss, and multiple myeloma. Front Endocrinol (Lausanne) 10. https:\/\/doi.org\/10.3389\/fendo.2018.00788","DOI":"10.3389\/fendo.2018.00788"},{"key":"6009_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.critrevonc.2016.07.006","volume":"105","author":"T Matthes","year":"2016","unstructured":"Matthes T, Manfroi B, Huard B (2016) Revisiting IL-6 antagonism in multiple myeloma. Crit Rev Oncol Hematol 105:1\u20134. https:\/\/doi.org\/10.1016\/j.critrevonc.2016.07.006","journal-title":"Crit Rev Oncol Hematol"},{"key":"6009_CR52","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/nri844","volume":"2","author":"F Mackay","year":"2002","unstructured":"Mackay F, Browning JL (2002) BAFF: a fundamental survival factor for B cells. Nat Rev Immunol 2:465\u2013475. https:\/\/doi.org\/10.1038\/nri844","journal-title":"Nat Rev Immunol"},{"key":"6009_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.3","author":"PJ Hengeveld","year":"2015","unstructured":"Hengeveld PJ, Kersten MJ (2015) B-cell activating factor in the pathophysiology of multiple myeloma: a target for therapy? Blood Cancer J. https:\/\/doi.org\/10.1038\/bcj.2015.3. 5:","journal-title":"Blood Cancer J"},{"key":"6009_CR54","doi-asserted-by":"publisher","first-page":"6179","DOI":"10.4049\/jimmunol.173.10.6179","volume":"173","author":"ZSM Rahman","year":"2004","unstructured":"Rahman ZSM, Manser T (2004) B cells expressing Bcl-2 and a signaling-impaired BAFF-Specific receptor fail to mature and are deficient in the formation of lymphoid follicles and Germinal centers. J Immunol 173:6179\u20136188. https:\/\/doi.org\/10.4049\/jimmunol.173.10.6179","journal-title":"J Immunol"},{"key":"6009_CR55","doi-asserted-by":"publisher","unstructured":"Bolli N, Maura F, Minvielle S et al (2018) Genomic patterns of progression in smoldering multiple myeloma. Nat Commun 9. https:\/\/doi.org\/10.1038\/s41467-018-05058-y","DOI":"10.1038\/s41467-018-05058-y"},{"key":"6009_CR56","doi-asserted-by":"publisher","first-page":"2604","DOI":"10.1038\/s41375-018-0037-9","volume":"32","author":"N Bolli","year":"2018","unstructured":"Bolli N, Biancon G, Moarii M et al (2018) Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups. Leukemia 32:2604\u20132616. https:\/\/doi.org\/10.1038\/s41375-018-0037-9","journal-title":"Leukemia"},{"key":"6009_CR57","doi-asserted-by":"publisher","first-page":"193","DOI":"10.23736\/S0031-0808.20.04148-8","volume":"62","author":"V MONTEFUSCO","year":"2020","unstructured":"MONTEFUSCO V, MUSSETTI A, SALAS MQ et al (2020) Old and new generation proteasome inhibitors in multiple myeloma. Panminerva Med 62:193\u2013206. https:\/\/doi.org\/10.23736\/S0031-0808.20.04148-8","journal-title":"Panminerva Med"},{"key":"6009_CR58","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1056\/nejmoa043445","volume":"352","author":"PG Richardson","year":"2005","unstructured":"Richardson PG, Sonneveld P, Schuster MW et al (2005) Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352:2487\u20132498. https:\/\/doi.org\/10.1056\/nejmoa043445","journal-title":"N Engl J Med"},{"key":"6009_CR59","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1111\/j.1365-2141.2004.05188.x","volume":"127","author":"S Jagannath","year":"2004","unstructured":"Jagannath S, Barlogie B, Berenson J et al (2004) A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 127:165\u2013172. https:\/\/doi.org\/10.1111\/j.1365-2141.2004.05188.x","journal-title":"Br J Haematol"},{"key":"6009_CR60","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1056\/nejmoa030288","volume":"348","author":"PG Richardson","year":"2003","unstructured":"Richardson PG, Barlogie B, Berenson J et al (2003) A phase 2 study of Bortezomib in Relapsed, Refractory Myeloma. N Engl J Med 348:2609\u20132617. https:\/\/doi.org\/10.1056\/nejmoa030288","journal-title":"N Engl J Med"},{"key":"6009_CR61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.leukres.2016.09.007","volume":"50","author":"GM Leclerc","year":"2016","unstructured":"Leclerc GM, Zheng S, Leclerc GJ et al (2016) The NEDD8-activating enzyme inhibitor pevonedistat activates the eIF2\u03b1 and mTOR pathways inducing UPR-mediated cell death in acute lymphoblastic leukemia. Leuk Res 50:1\u201310. https:\/\/doi.org\/10.1016\/j.leukres.2016.09.007","journal-title":"Leuk Res"},{"key":"6009_CR62","doi-asserted-by":"publisher","first-page":"4617","DOI":"10.1002\/cncr.30892","volume":"123","author":"JJ Shah","year":"2017","unstructured":"Shah JJ, Kaufman JL, Zonder JA et al (2017) A phase 1 and 2 study of Filanesib alone and in combination with low-dose dexamethasone in relapsed\/refractory multiple myeloma. Cancer 123:4617\u20134630. https:\/\/doi.org\/10.1002\/cncr.30892","journal-title":"Cancer"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-06009-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-06009-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-06009-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T20:09:51Z","timestamp":1735848591000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-06009-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,21]]},"references-count":62,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["6009"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-06009-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3995303\/v1","asserted-by":"object"}]},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,21]]},"assertion":[{"value":"28 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research was in line with the Declaration of Helsinki and approved by the Ethics Committee at Beijing Chao-Yang Hospital and Guizhou Medical University Hospital. Written informed consent was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}